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Purpose: The aim of this study was to evaluate the
cost-effectiveness of apixaban compared with to war-
farin, current standard of care, for stroke prevention
in patients with nonvalvular atrial ﬁbrillation (NVAF)
in Japan.
Methods: A previously published lifetime Markov
model was adapted to evaluate the cost-effectiveness
of apixaban compared with warfarin in patients with
NVAF in Japan. In the same model, the costs asso-
ciated with each clinical event and background mor-
tality were replaced with Japanese data. Whenever
available, some of the utility parameters were derived
from Japanese published literature. Lifetime horizon
was selected to evaluate the value of the treatment
beneﬁt (stroke prevention) against potential risks
(such as major bleedings) among patients with NVAF.
Direct medical cost, long-term care cost, and quality-
adjusted life years (QALYs) were calculated from the
payers’ perspective.
Findings: Compared with warfarin, treatment with
apixaban was estimated to increase life expectancy by
0.231 year or 0.240 QALYs while treatment cost
increased by ¥511,692 (US $5117 at an exchange rate
of US $1 ¼ ¥100). The incremental cost-effectiveness
ratio was ¥2,135,743 per QALY (US $21,357 per
QALY). On the basis of the results of the probabilisticDecember 2015sensitivity analysis, when the willingness-to-pay
threshold was set at approximately Z¥2,250,000
(US $22,500) per QALY, the probability of apixaban
being cost-effective was Z50%. Assuming a
willingness-to-pay threshold of ¥5,000,000 (US
$50,000) and ¥6,700,000 (US $67,000) in Japan,
the probability of apixaban being cost-effective was
85% and 91%, respectively.
Conclusion: Although most participants in the
Apixaban for Reduction in Stroke and Other Throm-
boembolic Events in Atrial Fibrillation (ARISTOTLE)
trial used for the efﬁcacy data of apixaban in the
model were non-Japanese patients, the impact of the
limitations on our results was considered small, and
our results were deemed robust because of the addi-
tional effect in Japanese patients compared with that
in the global population according to the subanalysis
of Japanese patients in the trial. Therefore, based on
an adaptation of a published Markov model, apix-
aban is a cost-effective alternative to warfarin in Japan
for stroke prevention among patients with NVAF.2837
Clinical Therapeutics(Clin Ther. 2015;37:2837–2851) & 2015 The Au-
thors. Published by Elsevier HS Journals, Inc.
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INTRODUCTION
Atrial ﬁbrillation (AF) affects 0.6% to 1.6% of the
general population and up to 14% of patients in
cardiovascular clinics in Japan.1,2 AF increases the
risk of stroke by nearly 5-fold.3 Warfarin has been
used to prevent the occurrence of stroke, a
complication of AF. However, monitoring of the
prothrombin time–international normalized ratio is
necessary during warfarin use, and it is not easy to
maintain the dose of the drug within the desired
therapeutic range.4 Use of warfarin can be
associated with hemorrhagic adverse effects,
including severe and life-threatening events, such as
intracerebral hemorrhage. In addition, warfarin is
complicated by challenges such as drug-drug interac-
tions and restriction of foods, including vitamin K.
Recent guidelines from the European Society of
Cardiology recommend the use of novel anticoagu-
lants (NOACs) as alternatives to warfarin or anti-
platelet therapy in most AF patients who require
stroke prevention.5
Apixaban, an orally active factor Xa inhibitor, has
been studied in a Phase III global randomized clinical
trial (Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation [ARIS-
TOTLE]) versus dose-adjusted warfarin in patients
with nonvalvular atrial ﬁbrillation (NVAF). The study
found that the incidence of stroke and systemic
embolism decreased signiﬁcantly and the frequency
of major bleeding also decreased signiﬁcantly in the
apixaban 5 mg BID group compared with the war-
farin control group.6 NOACs, such as dabigatran,
rivaroxaban, and apixaban, are currently available for
clinical use for the prevention of stroke in patients
with NVAF in Japan. According to the 2011 Estimates
of National Medical Care Expenditure report, the
medical cost of cerebrovascular diseases, including
ischemic and hemorrhagic stroke, was ¥1.8 trillion
(US $18 billion at an exchange rate of US $1 ¼¥100),
which accounted for approximately 6% of the overall
medical cost (¥28 trillion [US $280 billion]).7
Prevention of stroke is important not only clinically
but also from the perspective of health economics.2838High drug acquisition cost of NOACs versus warfarin
in Japan warrants such analyses to be conducted from
the Japanese payer perspective to inform selection of
optimal anticoagulation therapy for NVAF patients.
Warfarin is currently still considered the standard
of care, although NOACs are becoming more widely
used in Japan.8 In this study, we evaluated the cost-
effectiveness of apixaban compared with warfarin
based on Japanese data.METHODS
Model
In this study, a previously published model for
health economic evaluation9,10 (Figure 1) was adapted
to evaluate the cost-effectiveness of apixaban com-
pared with warfarin in Japan. The model was a
Markov model developed using Microsoft Excel,
and a 6-week cycle length was chosen to capture the
possibilities of events related to AF that occur within a
short period. The detailed description of the model
can be found in the publications by Dorian et al.9 In
brief, all patients started in the NVAF state, and
certain portions of the cohort were assigned during
each model cycle to one of the modeled 17 health
states. The health states comprised NVAF, ischemic
stroke (mild, moderate, severe), hemorrhagic stroke
(mild, moderate, severe), recurrent ischemic stroke
(mild, moderate, severe), recurrent hemorrhagic
stroke (mild, moderate, severe), systemic embolism,
gastrointestinal bleeding and myocardial infarction
(MI), and death. Intracranial hemorrhage (ICH) that
is not hemorrhagic stroke (other ICH), major bleeding
other than gastrointestinal bleeding, clinically relevant
nonmajor bleeding, and other cardiovascular hospi-
talization were also considered as events. Patients
who experience these events were assumed to stay
in their initially assigned anticoagulation state,
and events were modeled as transient states. These
assignments were based on the probability of
experiencing an event that in turn was derived from
secondary analyses of trial data9 (Tables I–IV). Some
events altered subsequent risks of modeled events,
including death (eg, patients with ischemic stroke
would have higher probability of death or patients
experiencing MI would have greater likelihood of
acute mortality). In addition, stroke severity was
considered. Stroke severity was evaluated by the
modiﬁed Rankin Scale (mRS) as mild (mRS scoresVolume 37 Number 12
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Figure 1. Markov model. The model uses a previously published 6-week cycle model.9,10 All patients start
with the nonvalvular atrial fibrillation (NVAF) state, and certain portions of the cohort are assigned
during each model cycle to 1 of the modeled 17 health states. The health states comprise ischemic
stroke (IS) (mild, moderate, severe), hemorrhagic stroke (HS) (mild, moderate, severe), recurrent IS
(mild, moderate, severe), recurrent HS (mild, moderate, severe), systemic embolism, gastrointest-
inal bleeding and myocardial infarction (MI), or death. Other intracranial hemorrhage (ICH), major
bleeding other than gastrointestinal bleeding, clinically relevant nonmajor (CRNM) bleeding, and
other cardiovascular hospitalization are also considered events, but patients are assumed to stay in
their initially assigned anticoagulation states and the events are modeled as transient states. Some
events altered the subsequent risks of modeled events, including death. AC = anticoagulant; ASA =
aspirin. M indicates Markov process, and triangles indicate that a patient transitions to the
following state in the next cycle.
I. Kamae et al.0–2), moderate (mRS scores 3–4), and severe (mRS
score 5; an mRS score of 6 is death). Recurrence was
also considered for stroke. For treatment after each
event, patients were assumed to continue the ﬁrst-line
treatment (apixaban or warfarin) after ischemic
stroke, systemic embolism, MI, clinically relevant
nonmajor bleeding, and other cardiovascular hospital-
ization. However, for ICH (including hemorrhagic
stroke), gastrointestinal bleeding, and other major
bleeding, patients were assumed to discontinue or
suspend ﬁrst-line treatment for 6 weeks. Patients
who discontinued ﬁrst-line treatment were assumedDecember 2015to start second-line aspirin treatment. In essence,
model structure was built to reﬂect real-life treatment
paradigms and consequences of treatment decision.
Localization
In the adaptation analysis, we used parameters
such as cost of each event and some of the utility
parameters and background mortality using the Jap-
anese data. The cost of the acute phase for each event
were obtained from Japanese claims data for patients
with AF (excluding AF associated with rheumatic
mitral valve disease and mechanical valve) using the2839
Table I. Distributions of the cTTR and CHADS2
scores used in the model.
Parameter Setting, % Source
cTTR, %
o52.38 25.00 Dorian et al,9 2014
52.38–66.02 25.00
66.02–76.51 25.00
Z76.51 25.00
CHADS2
0 0.60 Dorian et al,9 2014
1 33.40
2 35.80
3 18.00
4 8.70
5 3.10
6 0.40
CHADS2 ¼ congestive heart failure, hypertension, age
of 75 years, diabetes mellitus, stroke; cTTR ¼ center’s
median time in therapeutic range.
Clinical TherapeuticsMedical Data Vision Co Ltd (MDV) database. The
database provided claims data from 131 hospitals (as
of April 2013) using the Diagnosis Procedure Combi-
nation (DPC) system for medical service claims (21%
of general hospitals but 55% of general beds in Japan
is under the DPC system in 201415). DPC is a
reimbursement system for hospitals to claim a
treatment cost comprehensively estimated for one
hospitalization per patient. The actual costs per
event from admission until discharge (including
death; ie, mRS score of 6) with a name of each
event in the record of “disease name with the most
health resources invested” in DPC data were used to
estimate costs associated with the acute phase of each
event. The deﬁnitions of the target population and
events are given in Table V.
The costs of chronic stroke were obtained from the
study by Hattori et al, which included not only direct
medical cost but also the long-term care cost.16 The
cardiogenic brain embolism data derived from Stroke
Data Bank 2009 were used for distribution of the
mRS scores for each stroke severity in Japanese
patients.17 The cost of medication therapy and
that of percutaneous coronary intervention for the2840chronic phase of MI are quoted from the report of
Tanihata et al.18 The percentage of patients receiving
each treatment was obtained from a study using
claims data analysis in Japan by Evans et al.19
Because the research by Tanihata et al was
conducted in 2001, the cost derived from the study
was adjusted to 2014 rates based on the revised total
medical treatment fees thereafter (Tables VI and VII).
Japanese utility data were used only for chronic-
phase stroke, for which Japanese evidence is avail-
able16 (Table VIII). Background mortality was set
based on the 2012 Abridged Life Table according to
age and sex in Japan.20Analyses
Lifetime horizon was chosen to evaluate the
treatment value of the preventive effect against
events such as stroke in NVAF patients. The direct
medical cost, long-term care cost, and quality-
adjusted life-years (QALYs) were calculated from
the payers’ perspective. The number of events
avoided per 1,000 patients with NVAF during the
lifetime horizon was also evaluated. An annual
discount of 2% was applied to both the cost and
effectiveness in accordance with a Japanese guideline
for health economic analysis.21
In this study, the cost-effectiveness of apixaban
compared with warfarin was estimated in base case
analysis. One-way sensitivity analysis for each parameter
was conducted to conﬁrm the impact of each parameter
on the analysis results with the 95% CI for each
parameter. In addition, probabilistic sensitivity analysis
by Monte-Carlo simulation with 2000 iterations was
performed, and parameter uncertainty was assessed by
the cost-effectiveness acceptability curve, which plotted
the probability that apixaban is cost-effective in willing-
ness to pay (WTP) on the horizontal axis.RESULTS
Base Case Analysis
The simulation results in NVAF patients treated
with apixaban versus warfarin were projected to
reduce the number of strokes by 16 per 1000 patients
(2 for ischemic stroke and 14 for hemorrhagic stroke)
and the number of bleeding episodes other than
hemorrhagic stroke onset by 72 per 1000 patients.
The expected life-years accrued during lifetime treat-
ment per patient were 10.285 years for the warfarinVolume 37 Number 12
Table II. Relative event risks for each cTTR used in the model.*
cTTR
Relative Event Risk
SourceApixaban Warfarin
cTTR for stroke, %
o52.38 0.92 1.54 Dorian et al,9 2014
52.38–66.02 1 1 Dorian et al,9 2014
66.02–76.51 0.69 0.84 Dorian et al,9 2014
Z76.51 0.56 0.72 Dorian et al,9 2014
cTTR for ICH, %
o52.38 0.58 1.05 Dorian et al,9 2014
52.38–66.02 1 1 Dorian et al,9 2014
66.02–76.51 0.69 0.68 Dorian et al,9 2014
Z76.51 0.36 0.78 Dorian et al,9 2014
cTTR for gastrointestinal bleeding or other major bleeding, %
o52.38 0.72 0.84 Dorian et al,9 2014
52.38–66.02 1 1 Dorian et al,9 2014
66.02–76.51 1.69 1.13 Dorian et al,9 2014
Z76.51 1.77 1.37 Dorian et al,9 2014
cTTR for CRNM bleeding, %
o52.38 0.71 0.99 Dorian et al,9 2014
52.38–66.02 1 1 Dorian et al,9 2014
66.02–76.51 1.25 1.26 Dorian et al,9 2014
Z76.51 1.7 1.27 Dorian et al,9 2014
CRNM ¼ clinically relevant nonmajor bleeding; cTTR ¼ center’s median time in therapeutic range; ICH ¼ intracranial
hemorrhage.
*From the parameter applied in the model used in this analysis, settings for relative risk according to the cTTR of each event
are given. Event risk was set as the relative risk in each cTTR value based on a cTTR of 52.38% to 66.02%.
I. Kamae et al.group and 10.516 years for the apixaban group.
Therefore, apixaban was expected to extend 0.231
life-year and improve quality of life of patients, which
generated 0.240 QALYs gained. As with many new
technologies, innovation posts additional costs. The
clinical improvement from apixaban compared with
warfarin was expected to incur some additional costs
to Japanese payers. During a lifetime horizon, total
cost per patient was ¥5,144,019 (US $51,440) for
warfarin and ¥5,655,712 (US $56,557) for apixaban,
resulting in incremental cost of ¥511,692 (US $5117).
The incremental cost-effectiveness ratio (ICER) of
treatment with apixaban versus warfarin was esti-
mated to be ¥2,135,743 (US $21,357) per QALY
gained (Table IX).December 2015Sensitivity Analysis
The results of the 1-way sensitivity analysis identi-
ﬁed the following factors as having a large impact on
the ICER: the risk of ischemic and unspeciﬁed stroke
associated with the use of apixaban and the risk of
ICH associated with the use of warfarin (Figure 2).
The range of ICER in sensitivity analysis of these
parameters were ¥987,444 to ¥5,116,598 per QALY
(US $9,874 to $51,166 per QALY) for risk of
ischemic and unspeciﬁed stroke for apixaban and
¥832,334 to ¥3,819,575 per QALY (US $8323 to
38,196 per QALY) for risk of ICH for warfarin. In the
probabilistic sensitivity analysis, the cost-effectiveness
plane (scatterplot) suggested apixaban was more
effective and more costly than warfarin (Figure 3).2841
Table III. Clinical event rates for each parameter in the model.
Parameter Apixaban Warfarin Source
Event risk
Ischemic stroke
CHADS2 score of 0–1 0.52/100 person-years 1.09
* Dorian et al,9 2014
CHADS2 score of 2 0.95/100 person-years Dorian et al,
9 2014
CHADS2 score of Z3 1.53/100 person-years Dorian et al,
9 2014
ICH 0.33/100 person-years 2.39* Dorian et al,9 2014
Gastrointestinal bleeding or
other major bleeding
1.79/100 person-years 1.27* Dorian et al,9 2014
CRNM bleeding 2.08/100 person-years 1.43* Dorian et al,9 2014
MI 0.53/100 person-years 1.14* Dorian et al,9 2014
Systemic embolism 0.09/100 person-years 1.11* Dorian et al,9 2014
Other CV hospitalization 10.46/100 person-years 1.00* Dorian et al,9 2014
Withdrawal from treatment 13.18/100 person-years 1.08* Dorian et al,9 2014
Recurrence rate of stroke
Ischemic stroke 4.10/100 person-years Mohan et al,11 2009
Hemorrhagic stroke 3.00/100 person-years Mohan et al,11 2009
Hemorrhagic stroke and gastrointestinal bleeding, %
Hemorrhagic stroke out of ICH 77 64 Dorian et al,9 2014
Gastrointestinal bleeding out of
other major bleeding
38 35 Dorian et al,9 2014
Rate of change in treatment after bleeding event, %
Hemorrhagic stroke 100.00 Assumption
Other ICH 56.00 Claassen et al,12 2008
Gastrointestinal bleeding 25.00 Sorensen et al,13 2009
Other major bleeding 25.00 Sorensen et al,13 2009
Mortality of each event, %
Systemic embolism 9.40 Dorian et al,9 2014
MI (male) 10.80 Scarborough et al,14 2010
MI (female) 15.60 Scarborough 201014
Other ICH 13.00 Dorian et al,9 2014
Gastrointestinal bleeding or other
major bleeding
2.00 Dorian et al,9 2014
CHADS2 ¼ congestive heart failure, hypertension, age of 75 years, diabetes mellitus, stroke; CRNM ¼ clinically relevant
nonmajor bleeding; CV ¼ cardiovascular; ICH ¼ intracranial hemorrhage; MI ¼ myocardial infarction.
*Hazard ratio based on apixaban use.
Clinical TherapeuticsThe cost-effectiveness acceptability curve revealed that
when the WTP was approximately Z¥2,250,000 (US
$22,500) per QALY; the probability of apixaban
being cost-effectiveness was Z50% (Figure 4).2842DISCUSSION
In this analysis, the cost-effectiveness of apixaban
compared with warfarin in Japan was estimated
by using Japanese data applied into a previouslyVolume 37 Number 12
Table IV. Distributions of the severity after a stroke.
Parameter
Distribution, %
Source
Mild
(mRS Score, 0–2)
Moderate
(mRS Score, 3–4)
Severe
(mRS Score, 5)
Death
(mRS Score, 6)
After ischemic stroke
Apixaban 53 21 8 18 Dorian et al,9 2014
Warfarin 45 30 10 15
After hemorrhagic stroke
Apixaban 23 32 10 35 Dorian et al,9 2014
Warfarin 20 15 12 53
mRS ¼ modiﬁed Rankin Scale.
I. Kamae et al.published model.9,10 Compared with warfarin, treat-
ment with apixaban earned life-years gained of 0.231
and QALYs gained of 0.240. The original study by
Dorian et al reported that discounted life-years and
QALYs gain were much the same (mainly due to the
mortality from the most frequent event of ischemic
stroke in the apixaban arm, which was slightly higher
than that in warfarin arm [18% vs 15%]). Further-
more, the utility values of severe stroke in the Japanese
model were signiﬁcantly lower than those in the
original model, which increased the gain in QALYs
from stroke severity improvement by apixaban. These
ﬁndings could be attributed as the cause of our results
that the gain in QALYs was higher than the gain in
life-years. Higher gain in QALYs by treatment with
apixaban compared with gain in life-years suggests
that apixaban has a greater impact on the improve-
ment of patient’s quality of life than on his or her
extension in life-years. The ICER for treatment with
apixaban versus warfarin was ¥2,135,743 per QALY
(US $21,357 per QALY). Although no speciﬁc ICER
threshold has been set in Japan, according to Ohkusa
et al and Shiroiwa et al, the WTP to gain 1 QALY in
Japan is ¥6,700,000 per QALY (US $67,000 per
QALY) and ¥5,000,000 (US $50,000 per QALY)
per QALY, respectively.22,23 On the basis of the
reported estimates of the WTP, apixaban is considered
cost-effective by a payer’s perspective.
Other than the payer’s perspective, whether this
extra cost of apixaban for a marginal beneﬁt from
a new treatment is acceptable from a patient’sDecember 2015perspective may also be in question. A study by Hori
et al reported that patients were willing to pay ¥819
(US $8.2) per day for an alternative drug that does not
need monitoring or dietary restrictions, such as war-
farin.24 The daily cost of apixaban is approximately
¥550 (US $5.5) in Japan, out of which the amount
that a patient copays is ¥165 (US $1.7) (based on a
30% copayment requirement). Thus, a Japanese
patient’s copayment amount of apixaban is lower
than how much he or she is willing to pay.
In the cost-effective analysis, we conducted a one-
way sensitivity analysis that identiﬁed the risk of
ischemic and unspeciﬁed stroke associated with the
use of apixaban and the risk of ICH associated with
the use of warfarin to largely affect the results. We
also found that, at the higher at the higher end of the
CI, the probability of apixaban being cost-effective
with a WTP of ¥5,000,000 yen per QALY (US
$50,000 per QALY) and ¥6,700,000 per QALY (US
$67,000 per QALY) was 85% and 91%, respectively.
Consistent with the pivotal ARISTOTLE trial,6 our
analysis had warfarin only as the comparator. Studies
from other countries have reported that apixaban
was cost-effective when compared with other
NOACs.10,25,26,27,28 These studies were based on the
results estimated by indirect treatment comparison
among the ARISTOTLE trial (apixaban 5 mg BID vs
warfarin), the Randomized Evaluation of Long-Term
Anticoagulation Therapy (RE-LY) trial (dabigatran
110 mg BID vs dabigatran 150 mg BID vs warfarin),
and the Rivaroxaban Once Daily Oral Direct Factor2843
Table V. Definitions of target population and events for analysis from claims data.
Target population Patient with standard disease name, such as atrial ﬁbrillation or chronic atrial
ﬁbrillation, nonvalvular atrial ﬁbrillation, and nonvalvular paroxysmal atrial
ﬁbrillation. Atrial ﬁbrillation with the following conditions were excluded*: rheumatic
atrial ﬁbrillation (ICD code I05–I09 [chronic rheumatic disease]) and mechanical
valvular atrial ﬁbrillation (T820 [mechanical complication of prosthetic cardiac valve])
Deﬁnition of event
Ischemic stroke ICD code I63 (cerebral infarction)
Hemorrhagic
stroke
ICD code I60 (subarachnoid hemorrhage) and I61 (intracerebral hemorrhage)
Other ICH ICD code I62 (other nontraumatic intracranial hemorrhage)
Gastrointestinal
bleeding
ICD code K250 (gastric ulcer, acute and with bleeding)
K252 (gastric ulcer, acute and with bleeding and perforation)
K260 (duodenal ulcer, acute and with bleeding)
K262 (duodenal ulcer, acute and with bleeding and perforation)
K270 (peptic ulcer at unknown site, acute and with bleeding)
K272 (peptic ulcer at unknown site, acute and with bleeding and perforation)
K280 (gastrojejunal ulcer, acute and with bleeding)
K282 (gastrojejunal ulcer, acute and with bleeding and perforation)
K290 (acute hemorrhagic gastritis)
K920 (hematemesis)
K921 (melena)
K922 (gastrointestinal hemorrhage, details unknown)
MI ICD code I21 (acute myocardial infarction)
I23 (secondary complication of acute myocardial infarction)
Systemic embolism ICD code I26 (as pulmonary embolism), I74 (embolism of artery and thrombosis), I81
(portal vein thrombosis), I82 (other embolism of vein and thrombosis)
Other major
bleeding or
CRNM bleeding
All disease names including “bleeding” in the MDV data (excluding above intracranial
hemorrhage and gastrointestinal hemorrhage)
Other
cardiovascular
hospitalization
Below ICD codes in MDV data (excluding above ischemic stroke, intracranial
hemorrhage and systemic embolism)
I20–I25 (ischemic heart disease)
I26–I28 (pulmonary heart disease and pulmonary circulation disease)
I60–I69 (cerebrovascular disease)
I70–I79 (artery, arteriole and capillary disease)
I80–I89 (vein, lymphatic vessel and lymph node disease, not categorized in other
deﬁnition)
G45 (transient ischemic attack and related syndrome)
CRNM ¼ clinically relevant nonmajor bleeding; ICD ¼ International Classiﬁcation of Diseases; ICH ¼ intracranial
hemorrhage; MDV ¼ Medical Data Vision Co Ltd; MI ¼ myocardial infarction; mRS ¼ modiﬁed Rankin Scale.
*Patients under dialysis or cancer (these patients presents a great impact on the total medical cost).
Clinical Therapeutics
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Table VI. Antithrombotic drug costs.
Tablet
Size, mg
Cost per
Tablet, ¥
Mean Daily
Dose, mg
No. of Tablets
per Day
Mean Daily
Cost, ¥
Apixaban 5 272.8 10 2 545.6
Aspirin 100 10.0 100 1 10.0
Warfarin 1 10.0 5 5 50.0
I. Kamae et al.Xa Inhibition Compared with Vitamin K Antagonism
for Prevention of Stroke and Embolism Trial in Atrial
Fibrillation (ROCKET-AF) trial (rivaroxaban 20 mg
once daily vs warfarin).6,29,30 The RE-LY trial and
ROCKET-AF trial have different patient backgrounds
and study designs (the ROCKET-AF trial targets a
high-risk population, the RE-LY trial is open label,
but the ROCKET-AF and ARISTOTLE trials are
double-blind comparative trials), and the study dose
of rivaroxaban in the ROCKET-AF trial is different
from the Japanese approved dose (15 mg once daily).
In addition, because all these NOACs have the same
prices, it would be likely to have no incremental cost
between these NOACs in the Japanese setting of
clinical practice. Hence, inclusion of the other NOACs
was not adapted to comply with the standard ap-
proach of cost-effectiveness analysis.
As with all cost studies, our study presents several
limitations worth mentioning. First, we did not use
Japan-speciﬁc utility data except for chronic phase
stroke because of a lack of utility data for some event
states.16 In addition, as mentioned above, the utility
values of severe stroke in the Japanese model were
signiﬁcantly lower than those in the original model,
but the reason for the difference is unknown because
of a lack of data, such as a country comparative study
using the EQ-5D for stroke. Sakthong et al reported
that the difference in utility values of type 2 diabetes
mellitus was observed between the preference weights
in the United Kingdom, United States, and Japan,
revealing higher scores in the United States than in the
United Kingdom and Japan.31 The Japanese
researchers Shiroiwa et al also reported that there
was a difference between the utility scores for the
general population in Japan and the other countries.32
Those ﬁndings, however, come from general or mild
health condition of patients. It is conjectured that,
speciﬁc to countries, the utility scores differ in severeDecember 2015conditions more largely than in mild ones. Therefore,
the issue of discrepancy between the Japanese and
original utility values in the case of severe stroke is still
left for further investigations. However, in our
sensitivity analysis, we saw only a small impact
resulting from a change in the utility parameters.
The highest ICER in the sensitivity analysis on utility
parameters was ¥2,763,056 per QALY (US $27,631
per QALY) when the utility decrement of warfarin
parameter was set to the least favorable for apixaban,
that is, with no utility decrement for warfarin
(warfarin disutility of 0). We therefore believe that
using utility data from overseas would not
signiﬁcantly reverse our conclusion.
Second, the claims data provided by the MDV,
which was used as the data source of the acute-phase
cost for each event, were based on the actual treat-
ment data from 131 hospitals. The MDV database
represents only a proportion (9%) of the 1496
hospitals that have adopted the DPC system in Japan.
On the other hand, the patient compositions listed by
the major diagnostic categories in the MDV data are
similar to the 2012 Discharged Patient Survey by the
Ministry of Health, Labour and Welfare.15 Therefore,
it is reasonable to assume that the MDV claims data
are representative of the nationwide composition of
hospitalized patients and related costs. Moreover, we
found similarities in the literature that support our
results. On estimating the acute-phase cost of stroke
and MI, Toyonaga et al counted the cost of stroke in
171 patients admitted to several laborer hospitals in
2005 and reported an acute-phase cost of approxi-
mately ¥1,300,000 (US $13,000) for ischemic stroke,
¥1,500,000 (US $15,000) for intracerebral hemor-
rhage, and ¥3,800,000 (US $38,000) for subarach-
noid hemorrhage.33 These costs were similar to our
results of ¥1,401,931 (US $14,019) for acute-phase
ischemic stroke and ¥1,697,332 (US $16,973) for2845
Table VII. Cost parameters.
Parameter Cost, Mean (95% CI) ¥ Distribution SE, ¥ Source
Monitoring visit (warfarin only) 2120 Medical treatment fee
Routine care visit 720 Medical treatment fee
Mild ischemic stroke acute care (per episode) 1,024,406 (961,815–1,088,941) γ 32,434 Claims data
Mild ischemic stroke maintenance care (per month) 146,911 (138,299–155,780) γ 4460 Hattori 201216
Moderate ischemic stroke acute care (per episode) 1,699,225 (1,596,349–1,805,267) γ 53,301 Claims data
Moderate ischemic stroke chronic care (per month) 335,129 (319,427–351,203) γ 8107 Hattori et al,16 2012
Severe ischemic stroke acute care (per episode) 1,817,620 (1,698,097–1,941,151) γ 62,011 Claims data
Severe ischemic stroke chronic care (per month) 383,444 (361,995–405,502) γ 11,100 Hattori et al,16 2012
Fatal ischemic stroke (per episode) 983,728 (870,539–1,103,735) γ 59,509 Claims data
Mild hemorrhagic stroke acute care (per episode) 1,448,758 (1,140,846–1,792,900) γ 166,536 Claims data
Mild hemorrhagic stroke chronic care (per month) 157,117 (147,610–166,917) γ 4926 Hattori et al,16 2012
Moderate hemorrhagic stroke acute care (per episode) 2,131,870 (1,775,254–2,520,640) γ 190,286 Claims data
Moderate hemorrhagic stroke chronic care (per month) 336,541 (320,626–352,837) γ 8218 Hattori et al,16 2012
Severe hemorrhagic stroke acute care (per episode) 2,085,764 (1,576,334–2,665,429) γ 278,269 Claims data
Severe hemorrhagic stroke chronic care (per month) 383,444 (361,995–405,502) γ 11,100 Hattori et al,16 2012
Fatal hemorrhagic stroke (per episode) 902,966 (615,738–1,244,312) γ 160,798 Claims data
Systemic embolism acute care (per episode) 1,123,451 γ 83,844 Tanihata et al,18 2006
Evans et al,19 2007
Other ICH (excluding hemorrhagic stroke) 598,077 (515,908–686,230) γ 43,470 Claims data
Gastrointestinal bleeding 620,341 (556,760–687,311) γ 33,313 Claims data
Other major bleeding or CRNM bleeding 672,665 (567,485–786,656) γ 55,946 Claims data
MI acute care (per episode) 2,156,290 (1,940,641–2,383,138) γ 112,911 Claims data
MI chronic care (per month) 75,036 (71,981–78,153) γ 1575 Claims data
Other CV hospitalization 1,109,681 (1,050,043–1,170,944) γ 30,845 Claims data
CRNM ¼ clinically relevant nonmajor; CV ¼ cardiovascular; ICH ¼ intracranial hemorrhage; MI ¼ myocardial infarction.
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Table VIII. Utility parameters.
Parameter Mean (95% CI) Distribution SE Source
Utility value
Mild ischemic stroke 0.784 (0.758–0.809) β 0.013 Hattori et al,16 2012
Moderate ischemic stroke 0.443 (0.426–0.460) β 0.009 Hattori et al,16 2012
Severe ischemic stroke 0.092 (0.070–0.117) β 0.012 Hattori et al,16 2012
Mild hemorrhagic stroke 0.771 (0.746–0.795) β 0.013 Hattori et al,16 2012
Moderate hemorrhagic stroke 0.431 (0.414–0.448) β 0.009 Hattori et al,16 2012
Severe hemorrhagic stroke 0.092 (0.070–0.117) β 0.012 Hattori et al,16 2012
Systemic embolism 0.627 (0.589–0.664) β 0.019 Hattori et al,16 2012
Utility decrement
Other ICH 0.151 (0.081–0.238) β 0.040 Dorian et al,9 2014
Lip et al,10 2014
Gastrointestinal bleeding or
other major bleeding
0.151 (0.081–0.238) β 0.040 Dorian et al,9 2014
Lip et al,10 2014
CRNM bleeding 0.058 (0.029–0.096) β 0.017 Dorian et al,9 2014
Lip et al,10 2014
MI 0.610 (0.572–0.647) β 0.019 Dorian et al,9 2014
Lip et al,10 2014
Other CV hospitalization 0.128 (0.081–0.182) β 0.026 Dorian et al,9 2014
Lip et al,10 2014
Utility decrement due to anticoagulation treatment
Aspirin 0.002 (0.000–0.040) β 0.000 Dorian et al,9 2014
Lip et al,10 2014
Aspirin (second line) 0.002 (0.000–0.040) β 0.000 Dorian et al,9 2014
Lip et al,10 2014
Warfarin 0.013 (0.000–0.080) β 0.000 Dorian et al,9 2014
Lip et al,10 2014
CRNM ¼ clinically relevant nonmajor bleeding; CV ¼ cardiovascular; ICH ¼ intracranial hemorrhage; MI ¼ myocardial
infarction.
I. Kamae et al.hemorrhagic stroke (intracerebral hemorrhage:
¥1,599,116 [US $15,991]; subarachnoid hemorrhage:
¥2,614,010 [US $26,140]). Evans et al also reported
the cost for the acute phase of MI based on claims
data analysis, including 1748 admissions for MI to
several hospitals, as approximately ¥2,200,000 (US
$22,000),19 which is almost the same as the cost for
acute-phase MI of ¥2,156,290 (US $21,563) calcu-
lated in our analysis.
Despite the limitations we discussed, the impact of
these limitations on our results was considered small,
and our results were deemed robust because of theDecember 2015additional effect in Japanese patients compared with
that in the global population.
In conclusion, based on an adaptation of a pub-
lished Markov model, apixaban was a cost-effective
alternative to warfarin in Japanese NVAF patients by
lowering risks of clinical events, such as stroke and
bleeding and extending QALYs. Further research
extrapolating the cost-effectiveness of apixaban versus
warfarin with more representative and larger Japan-
speciﬁc real-world data or trial-based clinical data,
resource utilization, and utility data whenever avail-
able would be warranted.2847
Table IX. Results of base case analysis.
Warfarin Apixaban Difference
No. of events (per 1000 patients)
Stroke and systemic embolism* 358 341 17
Major bleeding, including hemorrhagic stroke* 263 220 43
CRNM bleeding 354 312 42
MI 94 92 2
Other CV hospitalization 1250 1283 33
Other treatment discontinuation 651 656 5
Outcomes (per patient)
Life-years 10.285 10.516 0.231
QALYs 7.23 7.469 0.24
Cost, ¥ 5,144,019 5,655,712 511,692
ICER, ¥ (per QALYs)
Discounted by 2% (base case) 2,135,743
Undiscounted 1,966,615
Discounted by 5% 2,393,753
CRNMB ¼ clinically relevant nonmajor; CV ¼ cardiovascular; ICER ¼ incremental cost-effectiveness ratio; ICH ¼
intracranial hemorrhage; MI ¼ myocardial infarction; QALYs: quality-adjusted life-years.
*Hemorrhagic strokes are considered in both categories.
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Figure 2. Results of 1-way sensitivity analysis (Tornado diagram). The analysis identified the following factors
as having a large impact on the cost-effectiveness of apixaban: the risk of ischemic and unspecified
stroke associated with the use of apixaban and the risk of intracranial hemorrhage (ICH) associated
with the use of warfarin. ICER = incremental cost-effectiveness ratio; MI = myocardial infarction;
PYs = patient-years; QALYs: quality-adjusted life-years.
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Figure 4. Results of probabilistic sensitivity analysis (cost-effectiveness acceptability curve). The cost-
effectiveness acceptability curve revealed that when the willingness to pay was approximately
Z¥2,250,000 (US $22,500) per quality-adjusted life-year QALY, the probability of apixaban
being cost-effectiveness was Z50%.
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Figure 3. Results of probabilistic sensitivity analysis (scatterplot). QALYs = quality-adjusted life-years.
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